I

Ionis Pharmaceuticals

D
IONS
USD
0.38
(0.8971%)
Market Closed
43,867.00
Volume
-4.598
EPS
-
Div Yield
-16.960317
P/E
6,740,572,029.34
Market Cap
Today
0.8971%
1 Week
4.142%
1 Month
-10.304%
6 Months
1.448%
12 Months
-0.582%
Year To Date
-15.500%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
B
BIIB
3.82
(1.9334%)
USD
GILD
GILD
0.015
(0.0179%)
USD
NVS
NVS
-0.02
(-0.0172%)
USD
REGN
REGN
11.33
(0.9948%)
USD
B
BMRN
0.31
(0.4359%)
USD
S
SRPT
1.96
(1.5667%)
USD
A
ARWR
0.35
(1.6851%)
USD
A
ANAB
0.87
(2.3783%)
USD
R
RARE
1.17
(2.0316%)
USD

Title:
Ionis Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Do you need help or have a question?
Contact Us